T. Rowe Price Associates
ADAP

T. Rowe Price Associates’s Adaptimmune Therapeutics ADAP Stock Holding History

T. Rowe Price Associates’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-73,922
Closed -$69K – 2890
2023
Q2 		$69K Buy
+73,922
New +$88.1K ﹤0.01% 2761

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates's ADAP Position: Q3 2023 in Review

T. Rowe Price Associates sold out of Adaptimmune Therapeutics (ADAP) in Q3 2023, closing a stake of 73,922 shares — an estimated $69K sold.

T. Rowe Price Associates first reported a position in ADAP in Q2 2023 and held it in 1 quarter. The position peaked at $69K in Q2 2023. 79 funds tracked by Wall St. Rank hold ADAP as of Q3 2023.

  • T. Rowe Price Associates reported no remaining Adaptimmune Therapeutics position as of Q3 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 73,922 Adaptimmune Therapeutics shares in Q3 2023, an estimated $69K.
  • T. Rowe Price Associates first reported a position in Adaptimmune Therapeutics in Q2 2023 and held it in 1 quarter.
  • T. Rowe Price Associates's Adaptimmune Therapeutics position peaked at $69K in Q2 2023.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2023.

Based on T. Rowe Price Associates's 13F filing for Q3 2023, filed 14 Nov 2023.